drugset / Trial / NCT06752720

Intracerebral Autologous Stem Cell Therapy for Chronic Stroke Patients

NCT06752720 ↗

NaSingle-groupOpen-labelTreatment

Summary

The goal of this clinical trial is to evaluate if autologous mesenchymal stem cell (HUNS001-01) transplantation therapy can provide neurological recovery in patients with chronic stage of stroke resulting in moderate to severe neurological sequelae. The main questions it aims to answer are: Can HUNS001-01 intracerebral transplantation demonstrate improvement in the mRS of disability for 1 year after intervention? Can HUNS001-01 intracerebral transplantation can be performed without any adverse events for 1 year after intervention? Participants will receive the below interventions. * Screening for the eligibility to enroll the clinical trial (interview, blood test, imaging) * Harvest of platelet concentrates (PC) * Harvest of bone marrows (BM) * Receive intracerebral transplantation surgery of HUNS001-01 * Post-operative rehabilitation * Follow-up studies (until 1 year or termination of the trial)

Timeline

Start
2024-12-01
Primary completion
2025-12-31
Completion
2027-11-30

Drugs

EvaluationDrugModalityDoseRoute
Subject HUNS001-01 Cell therapy 4e+07 cells Other

Indications